Business Wire

Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550

CARMEL, Ind.--(BUSINESS WIRE)--Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today ...
Business Wire

Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic

Funding to advance potential first- and best-in-class brain-penetrant TYK2 candidate in multiple sclerosis and potential first- and best-in-class topical dermal TYK2 candidate in psoriasis into the ...
Yahoo Finance

Sudo Biosciences Announces Positive Phase 1 Results for Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550

- SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration - Achieved exposure levels associated with >90% ...